Resistance benefits for Achillion's NS5A inhibitor as combos progress for HCV
This article was originally published in Scrip
Executive Summary
The US firm Achillion Pharmaceuticals has positive proof-of-concept data that justify further development of its second-generation, pan-genotypic NS5A inhibitor ACH-3102 to treat hepatitis C virus (HCV) as part of a combination therapy with ribavirin or the company's protease inhibitor sovaprevir (ACH-1625).